| __timestamp | Lantheus Holdings, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 72429000 | 7461000 |
| Thursday, January 1, 2015 | 78634000 | 11960000 |
| Friday, January 1, 2016 | 75374000 | 13108000 |
| Sunday, January 1, 2017 | 92157000 | 17501000 |
| Monday, January 1, 2018 | 93326000 | 22472000 |
| Tuesday, January 1, 2019 | 103132000 | 24286000 |
| Wednesday, January 1, 2020 | 110171000 | 29689000 |
| Friday, January 1, 2021 | 218817000 | 38837000 |
| Saturday, January 1, 2022 | 233827000 | 47489000 |
| Sunday, January 1, 2023 | 267194000 | 53379000 |
In pursuit of knowledge
In the competitive landscape of the healthcare sector, understanding the financial strategies of key players is crucial. Lantheus Holdings, Inc. and Xencor, Inc. have shown distinct patterns in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Lantheus Holdings has consistently increased its SG&A spending, peaking at approximately 267 million in 2023, marking a 270% rise from 2014. In contrast, Xencor, Inc. has maintained a more conservative approach, with its SG&A expenses growing by about 615% over the same period, reaching around 53 million in 2023. This divergence highlights Lantheus's aggressive expansion strategy compared to Xencor's steady growth. These insights provide a window into how these companies prioritize operational efficiency and market expansion, offering valuable lessons for investors and industry analysts alike.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
argenx SE and Xencor, Inc.: SG&A Spending Patterns Compared
Ascendis Pharma A/S and Lantheus Holdings, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc. Trends and Insights
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs ImmunityBio, Inc.
Operational Costs Compared: SG&A Analysis of Lantheus Holdings, Inc. and Ligand Pharmaceuticals Incorporated
Lantheus Holdings, Inc. and Novavax, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Operational Costs Compared: SG&A Analysis of Apellis Pharmaceuticals, Inc. and Xencor, Inc.
Comparing SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Xencor, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Xencor, Inc.
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Xencor, Inc.